AstraZeneca to invest $2.5bn in Beijing R&D hub, biotech partnerships, and vaccine manufacturing
AstraZeneca is investing $2.5 billion in Beijing for R&D, biotech partnerships, and vaccine production. Learn how this move impacts its market strategy. Read More
Harbour BioMed resubmits BLA for batoclimab to China’s NMPA for generalized myasthenia gravis
Harbour BioMed (HKEX: 02142), a prominent global biopharmaceutical company, has announced the resubmission of the Biologics License Application (BLA) for batoclimab (HBM9161) to the National ... Read More